drugset / Trial / NCT03571230
Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the First-line Helicobacter Pylori Eradication.
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to assess efficacy of 10-day antimicrobial susceptibility test guided triple therapy for the first-line treatment of Helicobacter pylori infection, then comparing it with 14-day empirical tailored therapy to tell which one has a better performance in both efficacy and safety.
Timeline
- Start
- 2018-07-01
- Primary completion
- 2019-12-30
- Completion
- 2020-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amoxicillin | Other / unclassified | 1000 mg | — |
| Subject | Clarithromycin | Small molecule | 500 mg | — |
| Subject | Furazolidone | Small molecule | 100 mg | — |
| Subject | Levofloxacin | Small molecule | 500 mg | — |
| Subject | Metronidazole | Small molecule | 500 mg | — |
| Subject | Tetracycline | Unknown | 750 mg | — |
| Subject | colloidal bismuth pectin | Unknown | 200 mg | — |
| Subject | tinidazole | Small molecule | 500 mg | — |
| Background | Lansoprazole | Other / unclassified | 30 mg | — |